Assessing the feasibility and benefits of Ketamine Sedation in Acute Brain Injury

Phase 2

Recruiting

• Conditions: Traumatic Brain Injury; Injuries and Accidents - Other injuries and accidents; Neurological - Other neurological disorders

• Registration Number: ACTRN12623000594628
• Lead Sponsor: Alfred Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-31
• Last Update Posted: 27 November 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

First admission to the intensive care unit (ICU) for management of moderate to severe traumatic brain injury with abnormal CT scan, Glasgow Coma Score <12 points and requirement from intracranial pressure monitoring
Clinically stable and sedated with an infusion of GABA agonist medication
Expected period of sedation >72hrs
For full active management

Exclusion Criteria

Pregnancy
Documented or suspected hypersensitivity to Ketamine
Known of suspected chronic kidney or liver disease
History of coronary artery disease or evidence of acute coronary syndrome
Admitted for palliative management
Greater than 72hrs elapsed since admission to the ICU

Study & Design

• Study Type: Interventional
• Study Design: Not specified